Alzamend Neuro is trading 6.74% down at $1.66 after reporting first-quarter fiscal 2027 EPS of $(0.68), missing the $(0.56) consensus estimate by 21.43%.
- Losses widened year over year, adding pressure to the clinical-stage biotechnology company.
- The decline is company-specific rather than broad-market driven.
- Major U.S. index futures were modestly higher on September 16, 2026.